Topics

Gallium Citrate Ga 67 Injection Rx only Diagnostic – For Intravenous Use | GALLIUM CITRATE GA-67 [Curium US LLC] | BioPortfolio

13:51 EST 27th January 2019 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Gallium Citrate Ga 67 Injection is supplied in a 10 milliliter vial as an isotonic, sterile, non-pyrogenic solution. Each milliliter of the isotonic solution contains 74 megabecquerels (2 millicuries) of gallium Ga-67 on the calibration date as a complex formed from 8.3 nanograms gallium chloride Ga-67, 1.9 milligrams of sodium citrate dihydrate, 7.8 milligrams of sodium chloride and 0.9 percent benzyl alcohol (v/v) as a preservative. The pH is adjusted to between 5.5 to 8.0 with hydrochloric acid and/or sodium hydroxide solution.

Gallium Ga-67, with a half-life of 78.26 hours, is cyclotron produced by the proton irradiation of enriched zinc. At the time of calibration the drug contains no more than 0.02% gallium Ga-66 and no more than 0.2% zinc Zn-65. The concentration of each radionuclidic impurity changes with time. At expiration, the drug contains no more than 0.001% gallium Ga-66 and no more than 1.0% zinc Zn-65. No carrier has been added.

Gallium citrate has the following chemical structure:

Gallium Ga-67 with a physical half-life of 78.26 hoursdecays by electron capture to stable zinc Zn-67. Photons that are useful for imaging studies are listed in Table 1.

Table 1. Principal Radiation Emission Data
Radiation Mean Percent Per
Disintegration
Energy
(keV)
Gamma-2 2.9 91.3
Gamma-3 35.7 93.3
Gamma-4 19.7 184.6
Gamma-5 2.2 209.0
Gamma-6 16.0 300.2
Gamma-7 4.5 393.5

The specific gamma ray constant for gallium Ga-67 is 1.6 R/mCi-hour at 1 cm. The first half-value thickness of lead (Pb) is 0.066 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of lead is shown in Table 2. For example, the use of 1.2 cm of lead will decrease the radiation exposure by a factor of about 100.

Table 2. Radiation Attenuation by Lead Shielding

To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in Table 3.

Table 3. Physical Decay Chart; Gallium Ga-67, Half-Life 78.26 Hours

* Calibration Time

Shield Thickness (Pb), cm Coefficient of Attenuation
0.066 0.41 1.2 2.5 4.8 0.5 10-1 10-2 10-3 10-4
Hours Fraction Remaining Hours Fraction Remaining
0* 6 12 18 24 (1d) 30 36 42 48 (2d) 54 60 66 1.000 0.948 0.899 0.853 0.809 0.767 0.727 0.689 0.654 0.620 0.588 0.557 72 (3d) 78 84 90 96 (4d) 108 120 (5d) 132 144 (6d) 156 168 (7d) 0.529 0.501 0.475 0.451 0.427 0.384 0.345 0.311 0.279 0.251 0.226

Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The mechanism of concentration is unknown, but investigational studies have shown that gallium Ga-67 accumulates in lysosomes and is bound to a soluble intracellular protein.

It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of gallium Ga-67 - other than tumors and sites of infection - is the renal cortex. After the first day, the maximum concentration shifts to bone and lymph nodes and after the first week, to liver and spleen. Gallium Ga-67 is excreted relatively slowly from the body. The average whole body retention is 65 percent after seven days, with 26 percent having been excreted in the urine and 9 percent in the stools.

Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.

None.

None known.

A thorough knowledge of the normal distribution of intravenously administered Gallium Citrate Ga 67 Injection is essential in order to accurately interpret pathologic states. The finding of an abnormal gallium Ga-67 concentration usually implies the existence of underlying pathology, but further diagnostic studies should be done to distinguish benign from malignant lesions. Gallium Citrate Ga 67 Injection is intended for use as an adjunct in the diagnosis of certain neoplasms as well as focal areas of infection. Certain pathologic conditions may yield up to 40 percent false negative gallium Ga-67 studies. Therefore, a negative study cannot be definitely interpreted as ruling out the presence of disease.

Lymphocytic lymphoma frequently does not accumulate gallium Ga-67 sufficiently for unequivocal imaging and the use of gallium with this histologic type of lymphoma is not recommended at this time.

Gallium Ga-67 localization cannot differentiate between tumor and acute inflammation, and other diagnostic studies must be added to define the underlying pathology.

As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient consistent with proper management and to ensure minimum radiation exposure to occupational workers.

The vial contents are sterile and non-pyrogenic. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides produced by nuclear reactor or particle accelerator and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether this drug affects fertility in males or females.

Animal reproductive studies have not been conducted with Gallium Citrate Ga 67. It is also not known whether Gallium Citrate Ga 67 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Gallium Citrate Ga 67 should be given to a pregnant woman only if clearly needed.

Ideally, examinations using radiopharmaceuticals, especially those elective in nature of women of childbearing capability, should be performed during the first few (approximately ten) days following the onset of menses.

This drug is known to be excreted in human milk during lactation, therefore, formula feedings should be substituted for breast feedings.

Safety and effectiveness in pediatric patients below the age of 18 have not been established.

Rare occurrences of allergic reactions, skin rash and nausea have been reported in association with Gallium Citrate Ga 67 use.

The recommended adult (70 kg) dose of Gallium Citrate Ga 67 Injection is 74 to 185 megabecquerels (2 to 5 millicuries). Gallium Citrate Ga 67 Injection is intended for intravenous administration only.

Approximately 10 percent of the administered dose is excreted in the feces during the first week after injection. Daily laxatives and/or enemas are recommended from the day of injection until the final images are obtained in order to cleanse the bowel of radioactive material and minimize the possibility of false positive studies.

Studies indicate the optimal tumor to background concentration ratios are often obtained 48 hours post injection. However, considerable biological variability may occur in individuals and acceptable images may be obtained as early as 6 hours and as late as 120 hours after injection.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if contents are turbid.

Instructions for the handling of Gallium Citrate Ga 67:

The estimated absorbed radiation dosesfrom an intravenous injection of 185 megabecquerels (5 millicuries) of Gallium Citrate Ga 67 are shown in Table 4.

Table 4. Absorbed Radiation Doses
 Tissue  mGy/
185MBq
 rads/
5mCi
 Whole Body  13.0  1.30
 Skeleton  22.0  2.20
 Liver  23.0  2.30
 Bone Marrow  29.0  2.90
 Spleen  26.5  2.65
 Kidney  20.5  2.05
 Ovaries  14.0  1.40
 Testes  12.0  1.20
 Gastrointestinal Tract    
    Stomach  11.0  1.10
    Small Intestine  18.0  1.80
    Upper Large Intestine  28.0  2.80
    Lower Large Intestine  45.0  4.50

Catalog Number 180.

Gallium Citrate Ga 67 Injection is supplied sterile and non-pyrogenic for intravenous use. Each milliliter contains 74 megabecquerels (2 millicuries) of gallium Ga-67 on the calibration date, as a complex formed from 8.3 nanograms gallium chloride Ga-67, 1.9 milligrams of sodium citrate dihydrate, 7.8 milligrams of sodium chloride, and 0.9 percent benzyl alcohol (v/v) as a preservative. The pH is adjusted to between 5.5 to 8.0 with hydrochloric acid and/or sodium hydroxide solution.

Gallium Citrate Ga 67 Injection is available in vials containing the following amounts on the calibration date.

Catalog No. N180G0 222 megabecquerels (6 mCi)NDC 69945-180-06 N180M0 444 megabecquerels (12 mCi)NDC 69945-180-12

The contents of the vial are radioactive, and adequate shielding and handling precautions must be maintained. Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

Storage and disposal of Gallium Citrate Ga 67 Injection should be controlled in a manner that is in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.

Curium and the Curium logo are trademarks of a Curium company.©2018 Curium US LLC. All Rights Reserved.

Manufactured by:Curium US LLCMaryland Heights, MO 63043

Made in USA

A180I0

R12/2018

CURIUM                                                                                                                                               

Gallium Citrate Ga 67 Injection

DIAGNOSTICSterile, Non-Pyrogenic SolutionFor Intravenous AdministrationStore at Controlled Room Temperature 20° to 25°C (68° to 77°F). Each mililiter contains 74 MBq (2 mCi) Gallium Citrate Ga 67 (essentially carrier free) at date and time of calibration, as a complex formed from 8.3 ng gallium chloride Ga 67, 1.9 mg sodium citrate dihydrate, 7.8 mg sodium chloride, and 0.9% (v/v), benzyl alcohol as a preservative. Sodium hydroxide or hydrochloric acid are added for pH adjustment. The pH is between 5.5 and 8.0. For information on dosage, administration and indications see package insert. Rx only. WARNING: Radioactive drugs must be handled only by qualified personnel in conformity with regulations of the U.S. Nuclear Regulatory Commission or state regulatory agencies where applicable. Bottle containing drug should be kept in this container or within heavier shield. Manufactured by:Curium US LLCMaryland Heights, MO 63043Made in USA

CURIUM

CAUTION RADIOACTIVE MATERIAL A180C0R12/2018

Manufacturer

Curium US LLC

Active Ingredients

Source

Drugs and Medications [245 Associated Drugs and Medications listed on BioPortfolio]

Gallium [lantheus medical imaging, inc.]

GALLIUM CITRATE Ga 67 INJECTION

Ganite [genta incorporated]

Ganite® (gallium nitrate injection)

Sildenafil citrate [greenstone llc]

These highlights do not include all the information needed to use SILDENAFIL CITRATE TABLETS safely and effectively. See full prescribing information for SILDENAFIL CITRATE TABLETS. SILDENAFIL CITRATE...

Sildenafil citrate [unit dose services]

These highlights do not include all the information needed to use SILDENAFIL CITRATE TABLETS safely and effectively. See full prescribing information for SILDENAFIL CITRATE TABLETS. SILDENAFIL CITRATE...

Acd solution modified [anazaohealth corporation]

ACD SOLUTION MODIFIED

Clinical Trials [538 Associated Clinical Trials listed on BioPortfolio]

68Ga-Citrate PET of Healthy Volunteers

This study investigates whole-body distribution kinetics of intravenously administered Gallium-69 (68Ga) citrate by positron emission tomography (PET)/computed tomography (CT). Thereafter,...

A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma

This is a single center imaging study investigating the use of PET with 68Ga-citrate in patients with DLBCL or BCLU.

Novel Gallium 68 Citrate in Orthopedic Infections

In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucos...

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

- Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. - Secondary Objective will be to evaluate the biodistribut...

Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participan...

PubMed Articles [332 Associated PubMed Articles listed on BioPortfolio]

Sodium citrate contributes to the platelet storage lesion.

Sodium citrate has become the preferred anticoagulant used for apheresis collection and has been included in commercial platelet additive solutions (PASs) since PAS-II. It was suggested that citrate b...

Surface Modification with Gallium Coating as Non-wetting Surfaces for Gallium-based Liquid Metal Droplet Manipulation.

We report gallium (Ga) coating as a simple approach to convert most common microfluidic substrates to non-wetting surfaces against surface-oxidized gallium-based liquid metal alloys. These alloys are ...

Liquid metal dispersion by self-assembly of natural phenolics.

Gallic acid, a natural phenolic compound, efficiently establishes surface complexes with liquid gallium leading to the formation of an aqueous gallium dispersion via sonication. The surface functional...

Impact of sodium citrate on structural properties of gluten.

The effect of sodium citrate on gluten-starch separation and physicochemical properties of gluten was studied. The results showed that the addition of sodium citrate to the dough caused to an improvem...

Measuring citrate synthase activity as an enzymatic approach to the differentiation of chilled and frozen/thawed meat.

Citrate synthase belongs between mitochondrial enzymes which are released from the meat tissue after cell membrane damage caused by ice crystal formation. The presence of this enzyme can indicate a pr...

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record